OBJECT: In this study, the feasibility of in vivo proton magnetic resonance spectroscopic imaging ((1)H MRSI) of the healthy human brain at a field strength of 9.4 T, using conventional acquisition techniques, is examined and the initial experience is summarized. MATERIALS AND METHODS: MRSI measurements were performed on a 9.4 T MR scanner (Siemens, Erlangen, Germany) equipped with head-only gradient insert (AC84, Siemens) and custom-developed, 8-channel transmit/24-channel receive, and 16-channel transmit/31-channel receive coils. Spectra were acquired from the superior part of the human brain with a modified STEAM sequence. Spectral quantification was done with LCModel software. RESULTS: Reasonable quality and signal-to-noise ratio of the acquired spectra allowed reliable quantification of 12 metabolites (Cramer-Rao lower bounds < 20 %), some of which may be difficult to quantify at field strengths below 7 T due to overlapping resonances or low concentrations. CONCLUSION: While further developments are necessary to minimize chemical shift displacement and homogeneity of the transmit field, it is demonstrated that in vivo (1)H MRSI at a field strength of 9.4 T is possible. However, further studies applying up-to-date techniques to overcome high-field specific problems are needed in order to assess the potential gain in sensitivity that may be offered by MRSI at 9.4 T.
OBJECT: In this study, the feasibility of in vivo proton magnetic resonance spectroscopic imaging ((1)H MRSI) of the healthy human brain at a field strength of 9.4 T, using conventional acquisition techniques, is examined and the initial experience is summarized. MATERIALS AND METHODS: MRSI measurements were performed on a 9.4 T MR scanner (Siemens, Erlangen, Germany) equipped with head-only gradient insert (AC84, Siemens) and custom-developed, 8-channel transmit/24-channel receive, and 16-channel transmit/31-channel receive coils. Spectra were acquired from the superior part of the human brain with a modified STEAM sequence. Spectral quantification was done with LCModel software. RESULTS: Reasonable quality and signal-to-noise ratio of the acquired spectra allowed reliable quantification of 12 metabolites (Cramer-Rao lower bounds < 20 %), some of which may be difficult to quantify at field strengths below 7 T due to overlapping resonances or low concentrations. CONCLUSION: While further developments are necessary to minimize chemical shift displacement and homogeneity of the transmit field, it is demonstrated that in vivo (1)H MRSI at a field strength of 9.4 T is possible. However, further studies applying up-to-date techniques to overcome high-field specific problems are needed in order to assess the potential gain in sensitivity that may be offered by MRSI at 9.4 T.
Authors: Vincent O Boer; Jeroen C W Siero; Hans Hoogduin; Jetse S van Gorp; Peter R Luijten; Dennis W J Klomp Journal: NMR Biomed Date: 2011-02-10 Impact factor: 4.044
Authors: Anna Andreychenko; Vincent O Boer; Catalina S Arteaga de Castro; Peter R Luijten; Dennis W J Klomp Journal: Magn Reson Med Date: 2011-12-28 Impact factor: 4.668
Authors: Małgorzata Marjańska; Edward J Auerbach; Romain Valabrègue; Pierre-François Van de Moortele; Gregor Adriany; Michael Garwood Journal: NMR Biomed Date: 2011-07-27 Impact factor: 4.044
Authors: Helen C Wu; Fabien Dachet; Farhad Ghoddoussi; Shruti Bagla; Darren Fuerst; Jeffrey A Stanley; Matthew P Galloway; Jeffrey A Loeb Journal: Epilepsia Date: 2017-07-17 Impact factor: 5.864
Authors: Seung-Kyun Lee; Jean-Baptiste Mathieu; Dominic Graziani; Joseph Piel; Eric Budesheim; Eric Fiveland; Christopher J Hardy; Ek Tsoon Tan; Bruce Amm; Thomas K-F Foo; Matt A Bernstein; John Huston; Yunhong Shu; John F Schenck Journal: Magn Reson Med Date: 2015-12-02 Impact factor: 4.668